Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Vepugratinib · 1 trial · 3 indications
ORR by Investigator Assessment.
PFS by blinded independent committee review (BICR).
| Arm | Type | Description |
|---|---|---|
| Vepugratinib + EV + Pembrolizumab (Safety Lead In) | EXPERIMENTAL | Vepugratinib administered orally with EV + pembrolizumab administered IV |
| Vepugratinib + Enfortumab Vedotin (EV) + Pembrolizumab | EXPERIMENTAL | Vepugratinib administered orally, and EV + pembrolizumab administered by intravenous (IV) infusion. |
| Placebo + EV + Pembrolizumab | PLACEBO_COMPARATOR | Placebo administered orally, and EV + pembrolizumab administered by IV infusion. |
| Name | Type | Description |
|---|---|---|
| Vepugratinib | DRUG | Administered orally |
| Placebo | OTHER | Administered orally |
| EV | DRUG | Administered by IV infusion |
| Pembrolizumab | DRUG | Administered by IV infusion |
Inclusion Criteria: * Have histologically confirmed, unresectable locally advanced or metastatic urothelial cancer (mUC). Individuals with mixed histology other than small cell or neuroendocrine carcinoma are eligible if a urothelial component is present. * Have a qualifying fibroblast growth facto...
Vepugratinib is an investigational small molecule being studied for the treatment of transitional cell carcinoma, a type of cancer that occurs in the urinary tract, including the urinary bladder. It is also being evaluated in patients with neoplasm metastasis, meaning cancer that has spread to other parts of the body.
Vepugratinib is a kinase inhibitor, as indicated by its '-tinib' suffix. Kinase inhibitors work by blocking specific enzymes called kinases, which are involved in cell signaling and growth. By inhibiting these kinases, Vepugratinib aims to interfere with the growth and spread of cancer cells.
Vepugratinib is being developed by Eli Lilly and Company, a pharmaceutical company traded on the stock exchange under the ticker symbol LLY. The company is conducting clinical trials to evaluate the drug's safety and effectiveness in patients with transitional cell carcinoma.
Vepugratinib is currently in Phase 3 clinical development. This means it is being studied in a large, late-stage trial to confirm its efficacy and monitor side effects in a larger patient population. It is still investigational and has not been approved by regulatory authorities.
Vepugratinib is being studied in a Phase 3 clinical trial with the identifier NCT07218380. This trial is recruiting participants with transitional cell carcinoma, urinary bladder neoplasms, and neoplasm metastasis. The study is randomized, double-blind, and placebo-controlled, with an estimated enrollment of 450 participants.
Yes, Vepugratinib is also known as LY3866288. In clinical trial NCT07218380, the drug is referred to by this alternative name. Both names refer to the same investigational drug being developed by Eli Lilly and Company for the treatment of urinary tract cancers.